MIC-HM40AB-100μg / 询价
MIC-HM40AB-500μg / 询价
MIC-HM40AB-500μgx2 / 询价
Biotinylated Human MICA Protein
Recombinant Biotinylated Human MICA Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Glu24-Gln308 [Accession | Q96QC4].
The protein has a predicted MW of 35.8 kDa. Due to glycosylation, the protein migrates to 60-68 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Biotinylated Human MICA on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human MICA is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human MICA, His Tag at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Human NKG2D, hFc Tag with the EC50 of 59.7ng/ml determined by ELISA (QC Test).
Immobilized Anti-MICA Antibody, hFc Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Human MICA, His Tag with the EC50 of 1.7μg/ml determined by ELISA.
TMICA (MHC class I chain-related gene A) is a transmembrane glycoprotein that functions as a ligand for human NKG2D. A closely related protein, MICB, shares 85% amino acid identity with MICA. These proteins are distantly related to the MHC class I proteins. They possess three extracellular Ig‑like domains, but they have no capacity to bind peptide or interact with beta 2-microglobulin.
FLJ60820; MGC111087; MICA; PERB11.1; DAMA-345G11.2; FLJ36918; FLJ60820; MGC21250
(1)Friese M A , Platten M , Lutz S Z , et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.[J]. Cancer Research, 2003, 63(24):8996-9006.
